LivingGLP1
Study S000358

Glucagon-like Peptide-1 (GLP-1) Agonists: Treatment Utilization Patterns and Risk of Acute Pancreatitis

ClinicalTrials.gov record

Registration

Registration
NCT01767389
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
1
Start
2012-09
Primary completion
2013-12
Lead sponsor
GlaxoSmithKline
Conditions
Diabetes Mellitus, Type 2
Interventions
OTHER:The GLP-1 receptor agonist users; OTHER:DPP-4 inhibitor users; OTHER:Other ADA users
Results posted
FALSE
Secondary identifiers
OTHER:WEUSKOP6477

Registered primary outcomes

  • For treatment utilization patterns: adherence will be assessed. [6 years]
  • For treatment utilization patterns: source of the index ADA (add-on, switch or new therapy) will be assessed. [6 years]
  • For treatment utilization patterns: treatment modification (discontinuation of the index ADA, switching of the index and concomitant ADA, and add-on therapy) will be assessed. [6 years]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.